SUMMARY This study examines whether the beneficial effects of molsydomine, a recently introduced antianginal agent, on exercise performance of patients with angina pectoris are long lasting. The hemodynamic effects are known to persist for several hours. The effects of molsydomine on the duration of exercise and the time to the onset of ST depression were compared to those of placebo during two hours after oral administration. Molsydomine prolonged the duration of exercise in all eight patients (average 2.8 min, P < 0.001) and delayed the onset of ST depression (average 2.2 min, P < 0.001), while the placebo failed to alter these measurements. The increment of the duration of exercise produced by 2 mg of molsydomine in two hours following oral administration was comparable to the increment produced in a few minutes after 0.3 mg of nitroglycerin given sublingually. The results indicate that molsydomine offers prophylaxis for angina pectoris that lasts at least two hours after oral administration.
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EFFORTS TO ACHIEVE LONGER THERAPEUTIC ACTION of drugs used in the prevention of angina pectoris have resulted in the introduction of a variety of nitrate preparations. Whether they offer truly long-lasting benefits in comparison with nitroglycerin still remains controversial. 1 Molsydomine (N-ethoxycarbonyl-3-morpholinosydnonimine), a recently introduced antianginal agent, exerts hemodynamic effects similar to those of nitroglycerin, 8" I but its effects are characteristically longer-lasting.8'-" Molsydomine can be given orally since hemodynamic effects exerted by an oral administration of this agent were similar to those obtained with sublingual administration. 10 Persistence of hemodynamic changes, however, may not be always correlated with a similar persistence of beneficial action on exercise capacity.' The efficacy of a drug in the prevention of angina is best evaluated by an acute study using a protocol with multistaged exercise tests." The present study was undertaken to examine the exercise performance of patients with angina pectoris during the two hours after oral administration.
Materials and Methods
Eight patients were studied. Criteria for inclusion in this study were 1) definite electrocardiographic evidence of myocardial ischemia during or after exercise stress testing; 2) presence of definable end-point of ischemia during exercise with typical angina pain; 3) absence of evidence of valvular heart disease, congestive heart failure, recent myocardial infarction or recent change in the frequency or severity of angina; 4) no history of taking digitalis for at least six weeks prior to the study.
Patients ranged in age from 51 to 71 14 16 18 These preliminary studies were done to familiarize patients with testing procedures and to test reproducibility of exercise performance.
On the day of the definitive investigation, the patients were studied in a fasting state in a warm room. They had neither smoked nor taken nitroglycerin the preceding three hours. The exercise protocol was designed following Redwood et Reproducibility of the study was examined by comparing the results between three control exercises, which were performed on each test day before drug treatment. Heart rate, systolic blood pressure, pressure-rate products before exercise and at the onset of angina as well as the time to the onset of angina and ST depression in control exercises are summarized in table 1. Values before exercise were obtained with the patient standing. None of these measurements was significantly different between any two test days, indicating that patient's condition before control exercise was similar on each test day and exercise performance was reproducible.
Effects on Exercise Capacity and ECG Changes
The effect of molsydomine on exercise capacity in two hours after oral administration was evaluated by comparing the duration of exercise the patient could perform before the onset of angina following an administration of molsydomine to that after placebo ( fig. 1) . After molsydomine the patients exercised an average of 7.3 ± 0.3 min before the onset of angina, which was 2.8 minutes longer as an average than the duration of exercise the patient could tolerate in control exercise done on the same day. After placebo the patients exercised 4.8 ± 0.2 minutes which was not different from the duration of exercise in the control study. The difference in the duration of exercise (the time to the onset of angina) between molsydomine and placebo was statistically signifi- fig. 1) .
On seven patients with ischemic changes appearing in the monitored lead during exercise, the time to the onset of ST depression as defined in methods was compared ( fig. 2 ). Placebo did not prolong the time to the onset of ST depression, but a delay in the time of these changes, by 2.2 min on the average, was noted in all patients after molsydomine (P < 0.001). An example of the delay of the onset of ST depression produced by molsydomine is shown in figure 3 . The ST segment was depressed after four minutes of exercise in the control study while a similar degree of ST depression was not observed until after six minutes of exercise following molsydomine.
Exercise capacity was increased by nitroglycerin in all patients ( fig. 4) . The average increase of the duration of exercise was 3.3 minutes (P < 0.001). The patients exercised to a workload at least one stage greater after nitroglycerin in control exercise ( fig. 4) figure 5 and figure 6. Values before exercise were obtained with the patient standing. Heart rate, systolic blood pressure, and pressure-rate products before exercise and at the onset of angina were not different between control exercise (shown in table 1) and exercise after placebo. Systolic blood pressure before exercise was lower (P < 0.01) and heart rate was higher (P < 0.05) following molsydomine and nitroglycerin in comparison to those after placebo (table 2, fig. 5 and fig. 6 ). Changes in heart rate and systolic blood pressure were comparable between molsydomine and nitroglycerin. Thus 2 mg of molsydomine in two hours after oral administration exerted hemodynamic changes at rest similar to those noted in a few minutes following 0.3 mg of nitroglycerin given sublingually.
Hemodynamic changes during exercise were compared after the same duration of exercise (three minutes of exercise) and at the onset of angina ( fig. 5 and fig. 6 ). After three minutes of exercise systolic blood pressure was lower following nitroglycerin (P < 0.05) and tended to be lower following molsydomine (0.05 < P < 0.1) than they were after placebo. However heart rate was not significantly higher following either drug. At the onset of angina, which occurred at the average of 4.8, 7.3, and 7.9 min of exercise with placebo, molsydomine and nitroglycerin respectively, systolic blood pressure was not different between the three, but heart rate was higher following nitroglycerin and molsyd- omine than after placebo (P < 0.01). As a result pressureangina is best evaluated,by an acute study using a protocol rate products at the onset of angina were higher following of multistage exercise." In order to evaluate drug effects on nitroglycerin and molsydomine than that after placebo.
exercise performance properly, the design of the protocol is important. The protocol should be able to demonstrate the Vasodilating effects of SIN-IA resemble those of nitroglycerin not only qualitatively but also quantitatively, effective both in capacitant as well as resistant vessels, rapid in the onset of action but transient, while those of molsydomine are slowly induced but long-lasting. 8 It is suggested that the differences in the onset and the duration of action of these compounds are due to the different rate of release of active principle. 8 Molsydomine is slow in the onset of action and long-lasting presumably because it has to be metabolized to the active forms to produce the effects.
Oral administration of molsydomine exerts as potent hypotensive effects as sublingual administration of this agent." After oral administration of 2 mg of molsydomine hypotensive effects in patients may last as long as 6 hours. 20 It is reported in the experimental study that molsydomine is easily absorbed from small intestine with about a half of the oral dose being absorbed during the first 30 minutes."
The way molsydomine works against angina in patients is not known. We examined hemodynamic changes at rest standing and during exercise produced by 2 mg of molsydomine in two hours after oral administration and compared them to changes observed a few minutes after 0.3 mg of nitroglycerin given sublingually. Changes in heart rate, systolic blood pressure, and pressure-rate products at rest and during exercise were similar between these two drugs ( fig. 5 and fig. 6 ). These results may suggest that the antianginal effects of molysodomine are produced in the similar way to those of nitroglycerin. Treatment with these drugs were associated with reduced systolic blood pressure and increased heart rate at rest, and with reduced or a tendency for reduction in systolic blood pressure during exercise in comparison to those with placebo. At the onset of angina systolic blood pressure after drugs was similar to that after placebo but heart rate was higher, resulting in higher pressure-rate products after drugs.
The result that heart rate after the same duration of exercise was not significantly higher following nitroglycerin or molsydomine than that after placebo in spite of a fall of blood pressure is somewhat different from the result previously reported by Goldstein et al. ' The difference between our study and that reported by Goldstein et al. may be due to the different dose of the drug used and the different group of patients examined. The reduction of blood pressure during exercise produced by the drugs was less in our study than that reported by Goldstein et al. In our study, although changes were not statistically significant as a group, heart rate was higher in seven of eight patients following nitroglycerin and six of eight patients following molsydomine than that was after placebo (table 2) . If the larger doses of the drugs were chosen with more reduction of blood pressure, significantly higher heart rate might have been noted following drugs than after placebo. In addition, the patients in our study were older than those studied by Goldstein et al. It is reported that baroreflex sensitivity in respect to reflex heart rate control is reduced as age increases." It is also known that exercise is associated with reduced baroreflex sensitivity." The latter may explain the less dramatic increase of heart rate during exercise than at rest in response to a fall of blood pressure. It is reported in the experimental study that molsydomine does not alter baroreflex."
In addition to the reducing effect on myocardial oxygen consumption by venous pooling," nitroglycerin may work against angina by redistributing regional myocardial blood flow favorably to the ischemic area.'4 Molsydomine may also affect the distribution of regional myocardial blood flow in the presence of chronic myocardial ischemia."5 Pressurerate products at the onset of angina, which are often used as the index of myocardial oxygen consumption,'8 were higher after molsydomine, as well as nitroglycerin, than they were after placebo. These results, however, do not imply that these two drugs increased myocardial oxygen delivery in these patients since other variables such as ejection time or ventricular size, which are also known to affect myocardial oxygen consumption,', " were not examined in this study.
In the study of Goldstein et al., nitroglycerin increased pressure-rate products at the time of angina, but when these values were multipled by ejection time the resulting triple products at angina were the same after nitroglycerin as they were after placebo. ' Molsydomine might produce transient headache, facial flush, orthostatic hypotension, gastrointestinal symptoms such as nausea, vomiting, diarrhea, and loss of appetite. Molsydomine may not be given to patients with glaucoma since it can increase intra-occular pressure. One of our patients complained of mild headache following an administration of 2 mg of molsydomine but no serious adverse effect was encountered.
